Nobelpharma Recruits Professor Chae Jonghee of Seoul National University Hospital as Scientific Advisory Member

Professor Jonghee Chae of the Department of Clinical Genomics Medicine at Seoul National University Hospital joins as a scientific advisory member of Nobelpharma
[Photo by Nobelpharma]

Rare drug specialist bio-venture Nobelpharma announced on the 18th that it has recruited Professor Jonghee Chae of the Department of Clinical Genomic Medicine at Seoul National University Hospital, an expert in pediatric rare diseases, as a member of its Scientific Advisory Board (SAB).

Nobelpharma has been jointly developing the innovative drug 'MPS III A' for Sanfilippo Syndrome Type A with GC Green Cross since 2020. With this recruitment, the company plans to accelerate clinical entry and new drug development for MPS III A. MPS III A was designated as a Rare Pediatric Disease Drug (RPDD) and an Orphan Drug (ODD) by the U.S. Food and Drug Administration (FDA) in January.

Professor Chae currently serves as the Director of the Rare Disease Center and the Central Support Center for Regional Hub Projects of the Rare Disease Center at Seoul National University Hospital. He has also served as the Director of the Biomarker Center at the Biomedical Research Institute of Seoul National University Hospital and as the Chair of the Scientific Committee of the Korean Child Neurology Society. Going forward, Professor Chae will play a key role in clinical design and protocol consultation.

A Nobelpharma official stated, "Professor Jonghee Chae, recognized as a leading expert in rare diseases, has joined the SAB to support U.S. clinical approval applications and global clinical entry. We will accelerate the development of the world's first treatment for Sanfilippo Syndrome Type A with a research team possessing extensive research experience and expertise."

This content was produced with the assistance of AI translation services.